O	0	10	Pathologic
O	11	14	and
O	15	24	molecular
O	25	34	responses
O	35	37	to
B-intervention	38	49	neoadjuvant
I-intervention	50	61	trastuzumab
I-intervention	62	65	and
I-intervention	65	66	/
I-intervention	66	68	or
I-intervention	69	78	lapatinib
O	79	83	from
O	84	85	a
O	86	91	phase
O	92	94	II
O	95	105	randomized
O	106	111	trial
O	112	114	in
O	115	119	HER2
O	119	120	-
O	120	128	positive
O	129	135	breast
O	136	142	cancer
O	143	144	(
O	144	148	TRIO
O	148	149	-
O	149	151	US
O	152	155	B07
O	155	156	)
O	156	157	.

O	158	160	In
O	161	165	this
O	166	177	multicenter
O	177	178	,
O	179	183	open
O	183	184	-
O	184	189	label
O	189	190	,
O	191	201	randomized
O	202	207	phase
O	208	210	II
O	211	223	investigator
O	223	224	-
O	224	233	sponsored
O	234	245	neoadjuvant
O	246	251	trial
O	252	256	with
O	257	264	funding
O	265	273	provided
O	274	276	by
O	277	283	Sanofi
O	284	287	and
O	288	303	GlaxoSmithKline
O	304	305	(
O	305	309	TRIO
O	309	310	-
O	310	312	US
O	313	316	B07
O	316	317	,
O	318	326	Clinical
O	327	333	Trials
O	334	345	NCT00769470
O	345	346	)
O	346	347	,
B-eligibility	348	360	participants
I-eligibility	361	365	with
I-eligibility	366	371	early
I-eligibility	371	372	-
I-eligibility	372	377	stage
I-eligibility	378	382	HER2
I-eligibility	382	383	-
I-eligibility	383	391	positive
I-eligibility	392	398	breast
I-eligibility	399	405	cancer
O	406	407	(
O	407	408	N
O	409	410	=
B-total-participants	411	414	128
O	414	415	)
O	416	420	were
O	421	430	recruited
O	431	435	from
O	436	438	13
B-location	439	445	United
I-location	446	452	States
O	453	461	oncology
O	462	469	centers
O	470	480	throughout
O	481	484	the
O	485	498	Translational
O	499	507	Research
O	508	510	in
O	511	519	Oncology
O	520	527	network
O	527	528	.

O	529	541	Participants
O	542	546	were
O	547	557	randomized
O	558	560	to
O	561	568	receive
B-control	569	580	trastuzumab
O	581	582	(
O	582	583	T
O	583	584	;
O	585	586	N
O	587	588	=
B-control-participants	589	591	34
O	591	592	)
O	592	593	,
O	594	603	lapatinib
O	604	605	(
O	605	606	L
O	606	607	;
O	608	609	N
O	610	611	=
B-intervention-participants	612	614	36
O	614	615	)
O	615	616	,
O	617	619	or
O	620	624	both
O	625	626	(
O	626	628	TL
O	628	629	;
O	630	631	N
O	632	633	=
B-intervention-participants	634	636	58
O	636	637	)
O	638	640	as
O	641	645	HER2
O	645	646	-
O	646	654	targeted
O	655	662	therapy
O	662	663	,
O	664	668	with
O	669	673	each
O	674	685	participant
O	686	691	given
O	692	695	one
O	696	701	cycle
O	702	704	of
O	705	709	this
O	710	720	designated
O	721	725	anti
O	725	726	-
O	726	730	HER2
O	731	738	therapy
O	739	744	alone
O	745	753	followed
O	754	756	by
O	757	760	six
O	761	767	cycles
O	768	770	of
O	771	779	standard
O	780	791	combination
O	792	804	chemotherapy
O	805	809	with
O	810	813	the
O	814	818	same
O	819	823	anti
O	823	824	-
O	824	828	HER2
O	829	836	therapy
O	836	837	.

O	838	841	The
O	842	849	primary
O	850	859	objective
O	860	863	was
O	864	866	to
O	867	875	estimate
O	876	879	the
B-outcome-Measure	880	884	rate
I-outcome-Measure	885	887	of
I-outcome-Measure	888	898	pathologic
I-outcome-Measure	899	907	complete
I-outcome-Measure	908	916	response
I-outcome-Measure	917	918	(
I-outcome-Measure	918	921	pCR
I-outcome-Measure	921	922	)
O	923	925	at
O	926	929	the
O	930	934	time
O	935	937	of
O	938	945	surgery
O	946	948	in
O	949	953	each
O	954	956	of
O	957	960	the
O	961	966	three
O	967	971	arms
O	971	972	.

O	973	975	In
O	976	979	the
O	980	986	intent
O	986	987	-
O	987	989	to
O	989	990	-
O	990	995	treat
O	996	1006	population
O	1006	1007	,
O	1008	1010	we
O	1011	1019	observed
O	1020	1027	similar
B-outcome	1028	1031	pCR
I-outcome	1032	1037	rates
O	1038	1045	between
O	1046	1047	T
O	1048	1049	(
B-cv-bin-percent	1049	1051	47
I-cv-bin-percent	1051	1052	%
O	1052	1053	,
O	1054	1056	95
O	1056	1057	%
O	1058	1068	confidence
O	1069	1077	interval
O	1078	1079	[
O	1079	1081	CI
O	1081	1082	]
O	1083	1085	30
O	1085	1086	-
O	1086	1088	65
O	1088	1089	%
O	1089	1090	)
O	1091	1094	and
O	1095	1097	TL
O	1098	1099	(
B-iv-bin-percent	1099	1101	52
I-iv-bin-percent	1101	1102	%
O	1102	1103	,
O	1104	1106	95
O	1106	1107	%
O	1108	1110	CI
O	1111	1113	38
O	1113	1114	-
O	1114	1116	65
O	1116	1117	%
O	1117	1118	)
O	1118	1119	,
O	1120	1123	and
O	1124	1125	a
O	1126	1131	lower
O	1132	1135	pCR
O	1136	1140	rate
O	1141	1145	with
O	1146	1147	L
O	1148	1149	(
B-iv-bin-percent	1149	1151	25
I-iv-bin-percent	1151	1152	%
O	1152	1153	,
O	1154	1156	95
O	1156	1157	%
O	1158	1160	CI
O	1161	1163	13
O	1163	1164	-
O	1164	1166	43
O	1166	1167	%
O	1167	1168	)
O	1168	1169	.

O	1170	1172	In
O	1173	1176	the
O	1177	1178	T
O	1179	1182	arm
O	1182	1183	,
B-cv-bin-percent	1184	1187	100
I-cv-bin-percent	1187	1188	%
O	1189	1191	of
O	1192	1204	participants
B-outcome	1205	1214	completed
I-outcome	1215	1218	all
I-outcome	1219	1227	protocol
I-outcome	1227	1228	-
I-outcome	1228	1237	specified
I-outcome	1238	1247	treatment
O	1248	1253	prior
O	1254	1256	to
O	1257	1264	surgery
O	1264	1265	,
O	1266	1268	as
O	1269	1277	compared
O	1278	1280	to
B-iv-bin-percent	1281	1283	69
I-iv-bin-percent	1283	1284	%
O	1285	1287	in
O	1288	1291	the
O	1292	1293	L
O	1294	1297	arm
O	1298	1301	and
B-iv-bin-percent	1302	1304	74
I-iv-bin-percent	1304	1305	%
O	1306	1308	in
O	1309	1312	the
O	1313	1315	TL
O	1316	1319	arm
O	1319	1320	.

O	1321	1326	Tumor
O	1327	1329	or
O	1330	1335	tumor
O	1336	1339	bed
O	1340	1346	tissue
O	1347	1350	was
O	1351	1360	collected
O	1361	1369	whenever
O	1370	1378	possible
O	1379	1382	pre
O	1382	1383	-
O	1383	1392	treatment
O	1393	1394	(
O	1394	1395	N
O	1396	1397	=
O	1398	1401	110
O	1401	1402	)
O	1402	1403	,
O	1404	1409	after
O	1410	1413	one
O	1414	1419	cycle
O	1420	1422	of
O	1423	1427	HER2
O	1427	1428	-
O	1428	1436	targeted
O	1437	1444	therapy
O	1445	1450	alone
O	1451	1452	(
O	1452	1453	N
O	1454	1455	=
O	1456	1458	89
O	1458	1459	)
O	1459	1460	,
O	1461	1464	and
O	1465	1467	at
O	1468	1472	time
O	1473	1475	of
O	1476	1483	surgery
O	1484	1485	(
O	1485	1486	N
O	1487	1488	=
O	1489	1491	59
O	1491	1492	)
O	1492	1493	.

O	1494	1500	Higher
O	1500	1501	-
O	1501	1506	level
O	1507	1520	amplification
O	1521	1523	of
O	1524	1528	HER2
O	1529	1532	and
O	1533	1540	hormone
O	1541	1549	receptor
O	1550	1551	(
O	1551	1553	HR
O	1553	1554	)
O	1554	1555	-
O	1555	1563	negative
O	1564	1570	status
O	1571	1575	were
O	1576	1586	associated
O	1587	1591	with
O	1592	1593	a
O	1594	1600	higher
B-outcome	1601	1604	pCR
I-outcome	1605	1609	rate
O	1609	1610	.

O	1611	1616	Large
O	1617	1623	shifts
O	1624	1626	in
O	1627	1630	the
O	1631	1636	tumor
O	1636	1637	,
O	1638	1644	immune
O	1644	1645	,
O	1646	1649	and
O	1650	1657	stromal
O	1658	1662	gene
O	1663	1673	expression
O	1674	1682	occurred
O	1683	1688	after
O	1689	1692	one
O	1693	1698	cycle
O	1699	1701	of
O	1702	1706	HER2
O	1706	1707	-
O	1707	1715	targeted
O	1716	1723	therapy
O	1723	1724	.

O	1725	1727	In
O	1728	1736	contrast
O	1737	1739	to
O	1740	1743	pCR
O	1744	1749	rates
O	1749	1750	,
O	1751	1754	the
O	1755	1756	L
O	1756	1757	-
O	1757	1767	containing
O	1768	1772	arms
O	1773	1782	exhibited
O	1783	1790	greater
O	1791	1804	proliferation
O	1805	1814	reduction
O	1815	1819	than
O	1820	1821	T
O	1822	1824	at
O	1825	1829	this
O	1830	1839	timepoint
O	1839	1840	.

O	1841	1847	Immune
O	1848	1858	expression
O	1859	1869	signatures
O	1870	1879	increased
O	1880	1882	in
O	1883	1886	all
O	1887	1891	arms
O	1892	1897	after
O	1898	1901	one
O	1902	1907	cycle
O	1908	1910	of
O	1911	1915	HER2
O	1915	1916	-
O	1916	1924	targeted
O	1925	1932	therapy
O	1932	1933	,
O	1934	1944	decreasing
O	1945	1950	again
O	1951	1953	by
O	1954	1957	the
O	1958	1962	time
O	1963	1965	of
O	1966	1973	surgery
O	1973	1974	.

O	1975	1978	Our
O	1979	1986	results
O	1987	1993	inform
O	1994	2004	approaches
O	2005	2007	to
O	2008	2013	early
O	2014	2024	assessment
O	2025	2027	of
O	2028	2039	sensitivity
O	2040	2042	to
O	2043	2047	anti
O	2047	2048	-
O	2048	2052	HER2
O	2053	2060	therapy
O	2061	2064	and
O	2065	2069	shed
O	2070	2075	light
O	2076	2078	on
O	2079	2082	the
O	2083	2087	role
O	2088	2090	of
O	2091	2094	the
O	2095	2101	immune
O	2102	2118	microenvironment
O	2119	2121	in
O	2122	2130	response
O	2131	2133	to
O	2134	2138	HER2
O	2138	2139	-
O	2139	2147	targeted
O	2148	2154	agents
O	2154	2155	.
